Mir Derikvandi, N (2020) The clinical use of Pembrolizumab as immunotherapy in treatment of PD-L1 positive non-small-cell lung cancer patients: a cost effectiveness analysis in the Netherlands. Master's Thesis / Essay, Biomedical Engineering.
|
Text
mBME_2020_MirderikvandiN.pdf Download (925kB) | Preview |
|
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
toestemming.pdf Restricted to Registered users only Download (113kB) |
Abstract
The purpose of this study was to investigate the cost-effectiveness of pembrolizumab as treatment in non-small lung cancer (NSCLC) versus platinum-based chemotherapy with paclitaxel plus cisplatin, with use of decision analytic modelling considering the long-term effects. However, the cost-effectiveness of pembrolizumab as treatment in NSCLC has not been yet assessed in the Netherlands. The aim of this study was to assess the potential cost-effectiveness of the two years treatment based on the recently published results of the Keynote-024 trial.
| Item Type: | Thesis (Master's Thesis / Essay) |
|---|---|
| Supervisor name: | Postma, M.J. |
| Degree programme: | Biomedical Engineering |
| Thesis type: | Master's Thesis / Essay |
| Language: | English |
| Date Deposited: | 12 Oct 2020 08:41 |
| Last Modified: | 12 Oct 2020 08:41 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/23483 |
Actions (login required)
 |
View Item |